stockrowOragenics, Inc.
OGEN Healthcare Biotechnology
Oragenics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $37,700.00, down 71.3% from fiscal 2022.
- EPS
- +81.6%
- Free cash flow
- −66.4%
Quarter to June 2026, against a year earlier
Follow OGEN
Alert me
Oragenics, Inc. (OGEN) EV/Sales
As of 6 November 2026, Oragenics, Inc. (OGEN) trades at a EV/Sales of 0.7×. Over the past ten years it has ranged from −63.3× (December 2025) to 116× (January 2024); the current reading is higher than 16% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 114× | 398.70% |
| FY2022 | 22.9× | (26.07%) |
| FY2021 | 31.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2023 | 31.0× | 74.01% |
| Jun 2023 | 17.8× | 445.68% |
| Mar 2023 | 3.3× | (95.21%) |
| Sep 2022 | 68.3× | 36.51% |
| 4 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| GOVX GeoVax Labs Inc. compare | −0.3× |
| CARM Carisma Therapeutics Inc. compare | 0.0× |
| GNPX GENPREX compare | n/m |
| PPCB Propanc Biopharma Inc compare | n/m |
| XRTX XORTX Therapeutics Inc. compare | n/m |
| KAPA Kairos Pharma, Ltd. compare | n/m |
| VRAX Virax Biolabs Group Limited compare | n/m |
| OGEN Oragenics, Inc. | 0.7× |
| ITRMF Iterum Therapeutics PLC compare | 24.4× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)